Linda F. Murphy

FDA investigator

Appears on 23 documents from 2015 to 2020, most often at sites in India. Most often cites design and construction features (21 CFR 211.42).

23
Documents on file
6.7
Observations per 483
2015
First seen
2020
Most recent

What they cite most

From 153 observations

Activity by year

2015: 2, 2016: 3, 2017: 3, 2018: 1, 2019: 11, 2020: 3

Where

India 6 · California 5 · Italy 2 · Japan 2 · Washington 2 · Colorado 1

Is Linda F. Murphy coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

23 documents, newest first
FirmOpen
483 First Pharma Associates LLCJun 7, 2020 · Spokane, Washington
483 Mylan Laboratories LimitedFeb 28, 2020 · Bengaluru, India
483 Somerset Therapeutics Private LimitedFeb 19, 2020 · Bengaluru, India
483 McGuff Compounding Pharmacy Services, Inc.Nov 22, 2019 · Santa Ana, California
483 Morton Grove PharmaceuticalsOct 31, 2019 · Morton Grove, Illinois
483 Bioduro LLCSep 6, 2019 · Irvine, California
483 Teva Parenteral Medicines, Inc.Aug 30, 2019 · Irvine, California

About this profile

What does Linda F. Murphy inspect?

Linda F. Murphy appears on 23 documents on file covering 22 sites, most often in India.

What do they cite most often?

21 CFR 211.42 (design and construction features), followed by 21 CFR 211.113 and 21 CFR 211.160.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Linda F. Murphy is dated Jun 7, 2020.